$COGT
Cogent Biosciences, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020013188 Filed on March 26, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q3
Revenue $7.031M $15.29M $1.020M
YoY Change 130.3% 301.79% -50.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.670M $2.690M $2.720M
YoY Change 47.39% 31.86% 14.77%
% of Gross Profit
Research & Development $9.498M $10.35M $10.34M
YoY Change -23.42% -3.9% 0.81%
% of Gross Profit
Depreciation & Amortization $300.0K $310.0K $320.0K
YoY Change -9.09% -11.43% -3.03%
% of Gross Profit
Operating Expenses $9.498M $13.05M $10.34M
YoY Change -23.42% 1.87% 0.81%
Operating Profit -$6.141M $2.240M -$12.04M
YoY Change -48.14% -124.88% 13.8%
Interest Expense $50.00K $60.00K $30.00K
YoY Change -66.67% -85.37% -92.68%
% of Operating Profit 2.68%
Other Income/Expense, Net $47.00K $0.00 $113.0K
YoY Change -68.67% -100.0% -72.3%
Pretax Income -$6.090M $2.300M -$11.92M
YoY Change -47.9% -126.71% 17.21%
Income Tax
% Of Pretax Income
Net Earnings -$6.094M $2.297M -$11.92M
YoY Change -47.87% -126.69% 17.26%
Net Earnings / Revenue -86.67% 15.02% -1168.92%
Basic Earnings Per Share $0.07 -$0.39
Diluted Earnings Per Share -$808.8K $0.07 -$0.39
COMMON SHARES
Basic Shares Outstanding 30.61M 30.66B 30.66B
Diluted Shares Outstanding 31.20B 30.66B

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.60M $37.40M $45.90M
YoY Change -55.89% -52.42% -47.3%
Cash & Equivalents $30.86M $37.42M $45.88M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.600M $1.200M $1.200M
YoY Change 100.0% 71.43% 20.0%
Inventory
Prepaid Expenses
Receivables $0.00 $2.000M $880.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $31.19M $40.59M $47.98M
YoY Change -55.39% -49.89% -46.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.570M $1.865M $2.170M
YoY Change -47.01% -42.63% -39.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $427.0K $847.0K
YoY Change 53.66% 1.91% 102.15%
Total Long-Term Assets $7.754M $8.832M $9.906M
YoY Change -31.86% 79.33% 87.37%
TOTAL ASSETS
Total Short-Term Assets $31.19M $40.59M $47.98M
Total Long-Term Assets $7.754M $8.832M $9.906M
Total Assets $38.94M $49.42M $57.88M
YoY Change -52.09% -42.48% -38.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $628.0K $3.183M $1.594M
YoY Change -65.8% 109.55% 98.51%
Accrued Expenses $6.900M $7.900M $7.000M
YoY Change 11.29% 43.64% 100.0%
Deferred Revenue $841.0K $1.315M $14.72M
YoY Change -95.03% -92.67%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.250M $13.25M $24.43M
YoY Change -64.89% -46.89% -7.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.000M $4.400M $4.800M
YoY Change -28.57% 528.57% 433.33%
Total Long-Term Liabilities $4.000M $4.400M $4.800M
YoY Change -28.57% 528.57% 433.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.250M $13.25M $24.43M
Total Long-Term Liabilities $4.000M $4.400M $4.800M
Total Liabilities $13.24M $17.66M $29.26M
YoY Change -58.62% -31.26% 7.36%
SHAREHOLDERS EQUITY
Retained Earnings -$130.0M -$123.9M -$126.2M
YoY Change 25.29% 34.58% 51.21%
Common Stock $155.7M $155.7M $154.8M
YoY Change 1.73% 2.2% 2.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.70M $31.76M $28.62M
YoY Change
Total Liabilities & Shareholders Equity $38.94M $49.42M $57.88M
YoY Change -52.09% -42.48% -38.93%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$6.094M $2.297M -$11.92M
YoY Change -47.87% -126.69% 17.26%
Depreciation, Depletion And Amortization $300.0K $310.0K $320.0K
YoY Change -9.09% -11.43% -3.03%
Cash From Operating Activities -$7.893M -$8.440M -$10.21M
YoY Change -31.47% -6.43% 34.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $20.00K
YoY Change -100.0% -122.22%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $200.0K
YoY Change -100.0% -100.0% -98.0%
Cash From Investing Activities $0.00 -$10.00K $220.0K
YoY Change -100.0% -100.07% -97.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $38.00K
YoY Change 245.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.00K 0.000 0.000
YoY Change 563.64% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.893M -8.440M -10.21M
Cash From Investing Activities 0.000 -10.00K 220.0K
Cash From Financing Activities 73.00K 0.000 0.000
Net Change In Cash -7.820M -8.450M -9.990M
YoY Change -327.13% -232.45% -498.01%
FREE CASH FLOW
Cash From Operating Activities -$7.893M -$8.440M -$10.21M
Capital Expenditures $0.00 -$10.00K $20.00K
Free Cash Flow -$7.893M -$8.430M -$10.23M
YoY Change -31.72% -6.54% 36.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
22923000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1668000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1167000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
40591000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5285000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3251000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1255000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
419000
CY2019Q4 us-gaap Assets
Assets
49423000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3183000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1519000
CY2019Q4 umrx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7131000
CY2018Q4 umrx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5477000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17949000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13248000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24945000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
748000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4413000
CY2019Q4 us-gaap Liabilities
Liabilities
17661000
CY2018Q4 us-gaap Liabilities
Liabilities
25693000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
155624000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
152275000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123892000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92059000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31762000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
60234000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49423000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85927000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24895670
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5308248
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30614600
CY2019Q2 dei Entity Public Float
EntityPublicFloat
40200000
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity File Number
EntityFileNumber
001-38443
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Cambridge Park Drive
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3100
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02140
CY2019 dei City Area Code
CityAreaCode
(617)
CY2019 dei Local Phone Number
LocalPhoneNumber
945-5576
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
CY2019 dei Trading Symbol
TradingSymbol
UMRX
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
740000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
81002000
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1321000
CY2018Q4 us-gaap Assets
Assets
85927000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10968000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
45739000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37424000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55671000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1865000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1255000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1619000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1315000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30663054
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30663054
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
54677000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-32178000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-36005000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1153000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30057970
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30057970
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9734000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
267000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
320000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
345000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1473000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-31833000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-34532000
CY2018 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
16000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31833000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34548000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30480330
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31821000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34528000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-48846000
CY2018Q4 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1
NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1
-6188000
CY2018 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
16000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
77167000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
609000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3088000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3241000
CY2019 us-gaap Profit Loss
ProfitLoss
-31833000
CY2018 us-gaap Profit Loss
ProfitLoss
-34532000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1293000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
53000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
246000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
78000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-10000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
23000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
332000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
838000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
250000
CY2019 umrx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1365000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
427000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
419000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1664000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
367000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1760000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2883000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-52000
CY2019 umrx Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-1472000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-16634000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3844000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41514000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32489000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
204000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
47682000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22988000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
37700000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23159000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10531000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
66793000
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5000000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
609000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2056000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70346000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18247000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27326000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56926000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29600000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
CY2018 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
77154000
CY2018 umrx Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
16000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and of Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at three accredited financial institutions. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party vendors for its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process. </p>
CY2019 umrx Deficiency Letter From Listing Qualifications Department Notifying Period
DeficiencyLetterFromListingQualificationsDepartmentNotifyingPeriod
P30D
CY2019Q4 umrx Minimum Bid Price Of Common Stock
MinimumBidPriceOfCommonStock
1.00
CY2019 umrx Initial Period To Regain Compliance With Minimum Bid Price Rule
InitialPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2019 umrx Additional Period To Regain Compliance With Minimum Bid Price Rule
AdditionalPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22935000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22923000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
485000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
75023000
CY2019Q4 umrx Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2018Q4 umrx Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6496000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6747000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4631000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3496000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2500000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1599000
CY2019Q4 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2987000
CY2018Q4 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1799000
CY2019Q4 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
750000
CY2018Q4 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
1015000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
894000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1064000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7131000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5477000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0215
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0264
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7407
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6740
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2200000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.50
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2019 umrx Tax Cuts And Jobs Act Of2017 Net Operating Losses Carryforward Maximum Percentage Of Taxable Income
TaxCutsAndJobsActOf2017NetOperatingLossesCarryforwardMaximumPercentageOfTaxableIncome
0.80
CY2019 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.055
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.042
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.016
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.301
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.307
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30055000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2220000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19189000
CY2019Q4 umrx Deferred Tax Assets Research And Development And Investment Tax Credits
DeferredTaxAssetsResearchAndDevelopmentAndInvestmentTaxCredits
6620000
CY2018Q4 umrx Deferred Tax Assets Research And Development And Investment Tax Credits
DeferredTaxAssetsResearchAndDevelopmentAndInvestmentTaxCredits
4891000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3294000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
644000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
437000
CY2019Q4 umrx Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
85000
CY2018Q4 umrx Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
93000
CY2019Q4 umrx Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
48000
CY2018Q4 umrx Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
60000
CY2019Q4 umrx Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
1444000
CY2019Q4 umrx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1648000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
831000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
933000
CY2019Q4 umrx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
38487000
CY2018Q4 umrx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
28897000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38487000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28897000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 umrx Operating Losses Carryforward Expiration Date
OperatingLossesCarryforwardExpirationDate
2035
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
79600000
CY2019Q4 umrx Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
28897000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
16611000
CY2019 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
9590000
CY2018 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
12286000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
38487000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-04-30
CY2019 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company’s option to extend for an additional five-year term.
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1772000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
1075000
CY2019 us-gaap Lease Cost
LeaseCost
2847000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2954000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M29D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0625
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1933000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1989000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2046000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
689000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6657000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
625000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6032000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1878000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1933000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1989000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2046000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
689000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8535000
CY2019Q4 us-gaap Purchase Obligation
PurchaseObligation
1000000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5043044
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3661982
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3138000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1020000
CY2019Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15288000
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1666000
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2043000
CY2018Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3805000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3053000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6986000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9439000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10576000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9004000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11841000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10541000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12036000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
2240000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6735000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-9023000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-10168000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-8606000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11691000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10516000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-11923000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
2297000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6751000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9023000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10168000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8606000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11691000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10516000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11923000
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2297000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10204591000
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29155790000
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29879476000
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30018342000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30083006000
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30505773000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30661125000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30663054000
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30505773000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30661125000
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31195620000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29879476000
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30018342000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30083006000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10204591000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29155790000

Files In Submission

Name View Source Status
0001564590-20-013188-index-headers.html Edgar Link pending
0001564590-20-013188-index.html Edgar Link pending
0001564590-20-013188.txt Edgar Link pending
0001564590-20-013188-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnw5v13y4yrm000001.jpg Edgar Link pending
gnw5v13y4yrm000002.jpg Edgar Link pending
gnw5v13y4yrm000003.jpg Edgar Link pending
gnw5v13y4yrm000004.jpg Edgar Link pending
gnw5v13y4yrm000005.jpg Edgar Link pending
gnw5v13y4yrm000006.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
umrx-10k_20191231.htm Edgar Link pending
umrx-20191231.xml Edgar Link completed
umrx-20191231.xsd Edgar Link pending
umrx-20191231_cal.xml Edgar Link unprocessable
umrx-20191231_def.xml Edgar Link unprocessable
umrx-20191231_lab.xml Edgar Link unprocessable
umrx-20191231_pre.xml Edgar Link unprocessable
umrx-ex231_623.htm Edgar Link pending
umrx-ex311_9.htm Edgar Link pending
umrx-ex312_8.htm Edgar Link pending
umrx-ex321_6.htm Edgar Link pending
umrx-ex322_7.htm Edgar Link pending
umrx-ex43_326.htm Edgar Link pending